ATE552837T1 - Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen - Google Patents

Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen

Info

Publication number
ATE552837T1
ATE552837T1 AT06840105T AT06840105T ATE552837T1 AT E552837 T1 ATE552837 T1 AT E552837T1 AT 06840105 T AT06840105 T AT 06840105T AT 06840105 T AT06840105 T AT 06840105T AT E552837 T1 ATE552837 T1 AT E552837T1
Authority
AT
Austria
Prior art keywords
high dose
immune disorders
treat immune
dose oxazaphosphorine
drugs
Prior art date
Application number
AT06840105T
Other languages
English (en)
Inventor
Robert Brodsky
Richard Jones
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE552837T1 publication Critical patent/ATE552837T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT06840105T 2005-12-02 2006-12-04 Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen ATE552837T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74217205P 2005-12-02 2005-12-02
PCT/US2006/061549 WO2007065167A1 (en) 2005-12-02 2006-12-04 Use of high-dose oxazaphosphorine drugs for treating immune disorders

Publications (1)

Publication Number Publication Date
ATE552837T1 true ATE552837T1 (de) 2012-04-15

Family

ID=37898760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06840105T ATE552837T1 (de) 2005-12-02 2006-12-04 Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen

Country Status (6)

Country Link
US (2) US20070202077A1 (de)
EP (2) EP1957082B1 (de)
AT (1) ATE552837T1 (de)
AU (1) AU2006320162B2 (de)
CA (1) CA2631760A1 (de)
WO (1) WO2007065167A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1957082B1 (de) * 2005-12-02 2012-04-11 The Johns Hopkins University Verwendung von hochdosierten oxazaphosphorin-arzneimitteln zur behandlung von immunstörungen
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
CN101883586A (zh) * 2007-10-01 2010-11-10 约翰斯霍普金斯大学 使用环磷酰胺治疗神经性自身免疫疾病
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs
US20090155207A1 (en) * 2007-11-29 2009-06-18 Hariri Robert J Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
WO2010011879A2 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
BRPI0917891A2 (pt) * 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
EP2350129B1 (de) 2008-08-25 2015-06-10 Amplimmune, Inc. Pd1-antagonistenzusammensetzungen und verfahren zu ihrer verwendung
US20120237472A1 (en) * 2009-07-24 2012-09-20 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
HUE031267T2 (en) 2010-11-23 2017-06-28 Abbvie Ireland Unlimited Co Methods of treatment using selective BCL-2 inhibitors
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
JP6401609B2 (ja) 2011-04-29 2018-10-10 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 抗体反応を低下させる寛容原性合成ナノキャリア
CN110841066A (zh) 2013-05-03 2020-02-28 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
PL405506A1 (pl) * 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US10105415B2 (en) 2014-07-24 2018-10-23 Reponex Pharmaceuticals A/S Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
BR112017001311A2 (pt) 2014-09-07 2017-11-14 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon
WO2016102530A1 (en) * 2014-12-22 2016-06-30 Bergen Teknologioverføring As Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome
EP3378492A4 (de) * 2015-11-20 2019-11-13 Kyushu University National University Corporation Immunregulatorischer wirkstoff
EP4360714A2 (de) 2016-09-21 2024-05-01 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
BR112019005292A2 (pt) 2016-09-21 2019-09-03 Nextcure Inc anticorpos para siglec-15 e métodos de uso dos mesmos.
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
AU2018329840A1 (en) 2017-09-07 2020-03-19 Augusta University Research Institute, Inc. Specific Akt3 activator and uses thereof
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
US20210032346A1 (en) 2018-01-23 2021-02-04 Nextcure, Inc. B7-h4 antibodies and methods of use thereof
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
US11116729B2 (en) 2019-01-17 2021-09-14 Georgia Tech Research Corporation Drug delivery systems containing oxidized cholesterols
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4841085A (en) * 1986-06-30 1989-06-20 Board Of Regents, University Of Texas System Aldophosphamides
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US5187266A (en) * 1986-06-30 1993-02-16 Board Of Regents The University Of Texas System Antitumor aldophosphamide glycoside and dideoxyuridine derivatives
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
JP2571119B2 (ja) * 1988-03-08 1997-01-16 株式会社中埜酢店 細胞膜結合型アルデヒド脱水素酸素の構造遺伝子、これを含むプラスミド、形質転換した酢酸菌及び酢酸発酵法
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
US5649904A (en) * 1988-10-07 1997-07-22 Sandoz Ltd. Method of treating cancer with a fully myeloablative regimen of chemotherapy, radiation or both
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
WO1998020932A2 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
US6447767B1 (en) * 1997-05-23 2002-09-10 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
CA2309919A1 (en) * 1997-11-14 1999-05-27 The General Hospital Corporation Treatment of hematologic disorders
IL122892A0 (en) * 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
US6562347B1 (en) * 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
WO1999058124A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
US6627759B1 (en) * 1998-12-07 2003-09-30 Duke University Method of isolating stem cells
US6879959B1 (en) * 2000-01-21 2005-04-12 Quality Care Solutions, Inc. Method of adjudicating medical claims based on scores that determine medical procedure monetary values
AU2001245550A1 (en) * 2000-03-09 2001-09-17 Lee Walters Applications of immune system tolerance to treatment of various diseases
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
WO2001089509A2 (en) * 2000-05-19 2001-11-29 Thomas Jefferson University Method of treating hiv-1 disease
WO2001091746A1 (en) * 2000-06-01 2001-12-06 The Mclean Hospital Corporation Method for treating alcohol intoxication and alcohol abuse
EP1450836A4 (de) * 2000-11-03 2007-07-25 Intarcia Therapeutics Inc Verfahren für die kurz- und langfristige dosierung von medikamenten
EP1368059A1 (de) * 2001-01-26 2003-12-10 Emory University Methoden zur induktion der organstransplantat-toleranz und zur korrektur von hämoglobinopathien
WO2002067968A2 (en) * 2001-02-21 2002-09-06 Emory University 14-3-3 binding molecules as sensitizers for anticancer therapies
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
NZ537366A (en) * 2002-06-27 2007-12-21 Endowment For Res In Human Bio Compounds useful for the inhibition of ALDH
MXPA05002453A (es) * 2002-09-05 2005-05-27 Bharat Serums & Vaccines Ltd Composicion estable liquida de oxazafosforina con el 2-mercaptoetansulfonato de sodio.
US7260249B2 (en) * 2002-09-27 2007-08-21 Confirma Incorporated Rules-based approach for processing medical images
PT1638589E (pt) * 2003-05-14 2014-06-12 Teva Pharma Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
JP2007532680A (ja) * 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド 疾患の治療方法
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
US20060253263A1 (en) * 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
JP4837357B2 (ja) * 2005-10-18 2011-12-14 エルピーダメモリ株式会社 半導体記憶装置
EP1957082B1 (de) * 2005-12-02 2012-04-11 The Johns Hopkins University Verwendung von hochdosierten oxazaphosphorin-arzneimitteln zur behandlung von immunstörungen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs

Also Published As

Publication number Publication date
WO2007065167A1 (en) 2007-06-07
AU2006320162A1 (en) 2007-06-07
EP2345412A1 (de) 2011-07-20
AU2006320162B2 (en) 2013-07-25
EP1957082A1 (de) 2008-08-20
US20110092462A1 (en) 2011-04-21
EP1957082B1 (de) 2012-04-11
CA2631760A1 (en) 2007-06-07
US20070202077A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
ATE552837T1 (de) Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
LTPA2016034I1 (lt) Brutono tirozinkinazės inhibitoriai
EA201300213A1 (ru) Применение ингибиторов dpp iv
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
CR6620A (es) Amino acidos biciclicos como agentes farmaceuticos
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
ATE453617T1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
Sinha et al. Hemimasticatory spasm: A case report with a new management strategy
ATE546159T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen enthaltend langwirksame beta-2-agonisten und wenigstens einen weiteren wirkstoff
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
RU2005122896A (ru) Способ оздоровления и коррекции биологического возраста
UA87139C2 (ru) Способ лечения поражений ветвей тройничного нерва